Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A
- PMID: 28299619
- DOI: 10.1007/s11605-017-3394-1
Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A
Abstract
The prognostic implications of the expression patterns of three tumor markers, alpha-fetoprotein (AFP), the Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des-γ-carboxy prothrombin (DCP), have been evaluated in patients with hepatocellular carcinoma (HCC). From January 1994 to December 2014, 1182 consecutive patients underwent hepatic resection and surgical microwave ablation for HCC at our institution. This study analyzed 475 patients within the Milan criteria and Child-Pugh class A. Cumulative overall survival (OS) and disease-free survival (DFS) rates were analyzed relative to the number of positive tumor markers. OS and DFS at 5 years postoperatively were 85.3 and 44.2% in triple-negative patients, 79.4 and 48.0% in single-positive patients, 56.2 and 32.9% in double-positive patients, and 61.7 and 35.7% in triple-positive patients with statistical significance. OS in triple-negative or single-positive patients was 85.3%, and that in all double- or triple-positive patients was 58.0% (P < 0.0001); DFS at 5 years postoperatively in these two groups was 45.9 and 34.0%, respectively (P < 0.0013). Both double- and triple-positive tumor markers are associated with early recurrence and poor survival in HCC patients within the Milan criteria and Child-Pugh class A.
Keywords: Alfa-fetoprotein; Des-γ-carboxy prothrombin; Hepatocellular carcinoma; Microwave ablation; Protein induced by vitamin K absence/antagonist-II.
Similar articles
-
Clinical Significance of Preoperative Hepatocellular Carcinoma With High Lens culinaris Agglutinin-reactive Fraction of Alpha-Fetoprotein, But Low Alpha-Fetoprotein.Anticancer Res. 2019 Feb;39(2):883-889. doi: 10.21873/anticanres.13189. Anticancer Res. 2019. PMID: 30711971
-
Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.Liver Transpl. 2015 May;21(5):599-606. doi: 10.1002/lt.24117. Liver Transpl. 2015. PMID: 25789635 Free PMC article.
-
Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.J Hepatol. 2008 Aug;49(2):223-32. doi: 10.1016/j.jhep.2008.04.013. Epub 2008 May 23. J Hepatol. 2008. PMID: 18571271
-
Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.Clin Liver Dis. 2015 May;19(2):309-23. doi: 10.1016/j.cld.2015.01.005. Epub 2015 Feb 27. Clin Liver Dis. 2015. PMID: 25921665 Review.
-
Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis.Biomed Res Int. 2020 Sep 17;2020:5087643. doi: 10.1155/2020/5087643. eCollection 2020. Biomed Res Int. 2020. PMID: 33015170 Free PMC article.
Cited by
-
Liquid Chromatography/Tandem Mass Spectrometry-Based Simultaneous Analysis of 32 Bile Acids in Plasma and Conventional Biomarker-Integrated Diagnostic Screening Model Development for Hepatocellular Carcinoma.Metabolites. 2024 Sep 23;14(9):513. doi: 10.3390/metabo14090513. Metabolites. 2024. PMID: 39330520 Free PMC article.
-
A Practical Model is Equivalent to the BALAD or BALAD-2 Score in Predicting Long-term Survival after Hepatectomy in Chinese Patients with Hepatocellular Carcinoma.J Cancer. 2021 Jan 1;12(5):1474-1482. doi: 10.7150/jca.51593. eCollection 2021. J Cancer. 2021. PMID: 33531992 Free PMC article.
-
Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade.J Gastrointest Surg. 2018 Jul;22(7):1230-1238. doi: 10.1007/s11605-018-3745-6. Epub 2018 May 7. J Gastrointest Surg. 2018. PMID: 29736665
-
Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.PLoS One. 2022 Mar 10;17(3):e0265235. doi: 10.1371/journal.pone.0265235. eCollection 2022. PLoS One. 2022. PMID: 35271670 Free PMC article.
-
Iron-sulphur cluster biogenesis factor LYRM4 is a novel prognostic biomarker associated with immune infiltrates in hepatocellular carcinoma.Cancer Cell Int. 2021 Sep 6;21(1):463. doi: 10.1186/s12935-021-02131-3. Cancer Cell Int. 2021. PMID: 34488769 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous